Recognizing symptoms in elderly patients with severe aortic stenosis (AS) can be a challenge. Serum biomarkers such as Galectin-3 or N-terminal prohormone B-type natriuretic peptide (NT-proBNP) are involved in remodeling and heart failure (HF) development and could support the diagnosis of AS. We set out to test the usefulness of NT-proBNP and Galectin-3 in predicting events in this population. We designed a prospective observational case-control study, including 50 asymptomatic patients older than 70 years, diagnosed with severe degenerative AS, and 50 control individuals. The NT-proBNP and Galectin-3 levels were measured. A follow-up was carried out at 12 months to determine the occurrence of hospital admission for HF, all-cause mortality or the appearance of symptoms. The patients with severe AS had higher Galectin-3 and NT-proBNP concentrations. The area under the receiver operating characteristic curve of the NT-proBNP was 0.812 (95% CI, 0.646-0.832), and that of the Galectin-3 was 0.633 (95% CI, 0.711-0.913). NT-proBNP was a good predictor of events [HR 3.45 (95% CI 1.32-9.03), = 0.011]. A Kaplan-Meier analysis showed that the probability of freedom from events was significant in patients who exhibited a combination of higher NT-proBNP and Galectin-3 levels (log-rank = 0.032). Therefore, NT-proBNP was the most reliable predictor of events in asymptomatic patients with severe AS. A combination of NT-proBNP and Galectin-3 levels may be vital in the clinical follow-up of these patients and in the decision-making process.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146298 | PMC |
http://dx.doi.org/10.3390/jcm12082987 | DOI Listing |
Curr Vasc Pharmacol
January 2025
Department of oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.
Purpose: The objective of this study was to explore the relationship among serum levels of the growth-stimulating expressed gene 2 protein (ST2), Galectin-3(GAL-3), N-terminal pro-B-type natriuretic peptide (NT-proBNP) in elderly hypertensive patients and heart failure with preserved ejection fraction (HFpEF).
Materials And Methods: Eighty-five elderly hypertensive patients with HFpEF were registered as the HFpEF group, and 46 hypertensive patients without HF were registered as the Non-HF group. The levels of serum sST2 (soluble ST2), Galectin-3, and NT-proBNP were measured, and related indexes of heart function were performed with echocardiography in two groups, respectively.
J Clin Med
January 2025
Department of Preventive Cardiology and Lipidology, Medical University of Lodz, 90-419 Lodz, Poland.
The Fontan operation has become the primary palliative treatment for patients with a functionally univentricular heart. The population of patients with Fontan circulation is constantly growing and aging. As the number of Fontan patients surviving into adulthood increases, there is a clear need for research on how best to follow these patients and manage their complications.
View Article and Find Full Text PDFClin Chim Acta
February 2025
Gilgamesh Ahliya University, Baghdad, Iraq. Electronic address:
Early detection and management of cardiovascular diseases (CVDs) are crucial for patient survival and long-term health. CVD biomarkers such as cardiac Troponin-I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase MB (CK-MB), Galectin-3 (Gal-3), etc are released into the circulation following heart muscle injury, ie, acute myocardial infarction (AMI). Biosensor technology including the use of nanoparticles can be designed to target specific biomarkers associated with CVD, enabling early detection and more rapid intervention to decrease morbidity and mortality.
View Article and Find Full Text PDFBMC Pulm Med
November 2024
Respiratory Care Clinic Tokyo, Institute of Clinical Respirology, 1-12-5-1F, Kyobashi, Chuo-ku, Tokyo, 104-0031, Japan.
Background: Cardiovascular disease is a common comorbidity in chronic obstructive pulmonary disease (COPD) and pre-COPD patients, contributing significantly to morbidity and mortality. We aimed to investigate whether Galectin-3 (Gal-3) levels correlate with cardiovascular biomarkers and cardiopulmonary function in COPD and pre-COPD patients to assess its potential role as a marker for cardiovascular comorbidity.
Methods: Community-dwelling adults with and without COPD were recruited.
Medicina (Kaunas)
November 2024
Department of Medical Biochemistry, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania.
: Heart failure (HF) is one of the most common initial presentations of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM). There are different cardiac biomarkers related to the pathophysiological mechanisms of HF in T2DM. The current research aims to identify additional biomarkers that could improve the diagnosis and prognosis of HFpEF, which is currently assessed using NT pro-BNP levels.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!